Browse the evidence

Weight reduction and management strategies may improve chronic kidney disease outcomes.

Weight management should be considered as part of CKD treatment plans.

Resistance-based exercise programs resulted in a significant change of +0.8 kg in lean mass (95% CI = 0.6 to 0.9 kg, P < 0.001).

Resistance training can effectively increase muscle mass in overweight and obese individuals.

Sustained improvements were noted in body mass (-7.6 %), HbA1c (-0.3 %), triglycerides (-18.4 %), HDL-C (+17.4 %), and inflammatory markers.

Practitioners can expect significant improvements in metabolic health markers with this dietary approach.

Both liraglutide (3 mg) and naltrexone/bupropion (32/360 mg) improved body weight and composition, carbohydrate and lipid metabolism, and liver fat and function.

Practitioners can consider both liraglutide and naltrexone/bupropion as effective options for improving metabolic health in patients with obesity.

Nutritional intake guidelines can be individualized to target multiple long-term conditions.

Nutrition plans should be customized to address specific health conditions.

CLA supplementation is associated with increased muscle variables or decreased adiposity variables.

CLA may be beneficial for individuals looking to improve muscle mass or reduce fat.

Body composition improved with losses in fat mass and gains in overall proportion of lean muscle and skeletal muscle.

Practitioners can expect improvements in body composition with semaglutide treatment.

Advances in metabolic surgery, pharmacologic therapy, and lifestyle modification have made remission of diabetes more feasible.

Healthcare providers should consider these advancements when discussing treatment options.

Meal replacement (MR) significantly reduced glycated hemoglobin A1c (HbA1c) by -0.46%, fasting blood glucose (FBG) by -0.62 mmol/L, body weight by -2.43 kg, and body mass index (BMI) by -0.65 compared to conventional diabetic diets (CDs).

Implementing meal replacement strategies can lead to significant improvements in glycemic control and weight management for T2D patients.

Total meal replacement showed greater improvement in HbA1c, FBG, body weight, and BMI compared to partial meal replacement.

Total meal replacement may be more effective than partial meal replacement for improving health markers in T2D patients.

Evidence-based nutritional and lifestyle strategies are crucial for effective GLP-1 treatment.

Clinicians should integrate nutritional and lifestyle interventions to enhance GLP-1 treatment outcomes.

Weight loss can improve obesity-related comorbidities such as metabolic syndrome, diabetes, cardiovascular disease, and obstructive sleep apnea.

Weight loss should be emphasized in preoperative counseling for patients with obesity.

Diabetes remission occurred in five GB participants and no medical participants (relative risk 0.76, 95% CI: 0.55-0.93, p = .048).

GB surgery may increase the likelihood of diabetes remission in overweight individuals with type 2 diabetes.

Weight-lowering approaches such as bariatric surgery and treatment with semaglutide and tirzepatide can alleviate both cardiovascular diseases (CVD) and nonalcoholic fatty liver disease (NAFLD).

Practitioners should consider weight loss interventions as effective strategies for managing NAFLD and CVD.

A minimal amount of weight loss can resolve NAFLD in lean patients.

Even small weight loss should be encouraged in lean patients with NAFLD for potential resolution of the condition.

Obesity significantly increases the risk of both nonalcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD).

Addressing obesity is crucial for reducing the risk of NAFLD and CVD in patients.

Exercise is a well-established measure to prevent or mitigate the adverse consequences of obesity.

Encouraging exercise can be a key strategy in obesity management.

Participants with higher adherence scores for an overall low-carbohydrate diet (LCD) exhibited lower odds of hepatic steatosis (OR = 0.76, 95% CI: 0.61-0.96, p trend = 0.049).

Encouraging adherence to low-carbohydrate diets may reduce the risk of hepatic steatosis.

Replacing 5% of the energy from carbohydrates with total fat and protein is associated with lower steatosis prevalence (OR = 0.91, 95% CI: 0.83-0.99).

Modifying carbohydrate intake by increasing fat and protein may help lower the risk of hepatic steatosis.

Excess adiposity is associated with worse outcomes in breast cancer survivors.

Practitioners should consider addressing excess adiposity in breast cancer survivors to improve health outcomes.

Excess adiposity can be targeted to improve breast cancer outcomes.

Interventions aimed at reducing excess adiposity may enhance survivorship and quality of life for breast cancer survivors.

Tirzepatide-associated improvements in cardiometabolic risk factors are positively related to the degree of weight reduction.

Weight reduction through tirzepatide can lead to significant improvements in cardiometabolic health.

Improvements in triglycerides, HDL cholesterol, LDL cholesterol, and non-HDL cholesterol were primarily observed after weight reductions greater than 10%.

Targeting a weight reduction of over 10% may be necessary for significant improvements in lipid profiles.

The steepest improvements in cardiometabolic risk factors occurred between less than 5% and less than 20% weight reduction.

Practitioners should note that even modest weight loss can lead to significant health improvements, particularly within the 5-20% range.